Heat Biologics, Inc. Announces Pricing of Initial Public Offering of 2,500,000 Shares of Common Stock
(firmenpresse) - CHAPEL HILL, NC -- (Marketwired) -- 07/23/13 -- Heat Biologics, Inc., a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, today announced the pricing of its initial public offering of 2,500,000 shares of its common stock at an initial public offering price of $10.00 per share. The gross proceeds to Heat Biologics from the offering are $25,000,000, before underwriting discounts and commissions and other offering expenses payable by Heat Biologics. Heat Biologics has granted the representative of the underwriters a 45-day option to purchase up to 375,000 additional shares of common stock from the Company to cover over-allotments, if any. Shares of Heat Biologics' common stock have been approved for listing on The NASDAQ Capital Market, under the symbol "HTBX" beginning on July 24, 2013.
The offering is expected to close on July 29, 2013, subject to customary closing conditions.
Aegis Capital Corp. is acting as sole book-running manager for the offering.
Cantor Fitzgerald & Co. is acting as a co-manager for the offering.
This offering is being made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, New York 10019, telephone: 212-813-1010, e-mail: .
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 23, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Heat Biologics () is a clinical-stage biopharmaceutical company focused on developing its novel off-the-shelf ImPACT therapeutic vaccines to combat a wide range of cancers. Our proprietary ImPACT Therapy is being designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat shock protein gp-96 is a chaperone protein found in all human cells. Heat's lead compound, HS-110, will be entering Phase 2 trials against non-small cell lung cancer and its second product candidate, HS-410 will be entering Phase 1/2 clinical trials against bladder cancer.
Matthew Czajkowski
Chief Financial Officer
(919) 240 7133
Rhonda Chiger
Rx Communications Group
(917) 322-2569
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.07.2013 - 16:19 Uhr
Sprache: Deutsch
News-ID 1248158
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
CHAPEL HILL, NC
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 244 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Heat Biologics, Inc. Announces Pricing of Initial Public Offering of 2,500,000 Shares of Common Stock
"
steht unter der journalistisch-redaktionellen Verantwortung von
Heat Biologics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
